Latest & greatest articles for fluoroquinolones

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoroquinolones or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoroquinolones and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoroquinolones

1. Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears

Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears - ACOG Menu ▼ Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Page Navigation ▼ Share: Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears (Replaces July 20, 2018, ACOG Practice Advisory, “New FDA Safety Warning for Fluoroquinolone (...) Antibiotics”) The U.S. Food and Drug Administration (FDA) has updated its drug safety information for oral and injectable fluoroquinolone antibiotics to include the rare but serious risk of aortic ruptures or tears in certain patients (1). The FDA advises that health care providers should not prescribe systemic fluoroquinolones for patients who have an aortic aneurysm or are at risk of an aortic aneurysm (such as patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic

2019 American College of Obstetricians and Gynecologists

3. Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness (...) , Cost-Effectiveness, and Guidelines Last updated: April 24, 2019 Project Number: RC1095-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of otitis media in patients unable to take beta-lactams antibiotics? What is the cost-effectiveness of fluoroquinolones for the treatment of otitis media in patients unable to take beta-lactams antibiotics? What are the evidence

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Intra (...) -Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 25, 2019 Project Number: RC1094-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of intra-abdominal infections? What is the cost-effectiveness of fluoroquinolones for the treatment of intra-abdominal infections? What are the evidence-based guidelines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness,

Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Last updated: May 6, 2019 Project Number (...) : RC1093-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What are the evidence-based guidelines for the use of fluoroquinolones for the treatment of respiratory tract infections? Key Message Overall, 15 publications met the eligibility

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones (...) for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 31, 2019 Project Number: RC1123-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract (...) Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 26, 2019 Project Number: RC1101-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of urinary tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of urinary tract infections? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation (Abstract)

Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation Recent studies have linked fluoroquinolones (FQs) to cardiac adverse events, including aortic dissection and aneurysm. To date, whether FQs can increase the risk of aortic or mitral regurgitation has not been studied.This disproportionality analysis and case-control study examined whether FQs increase the risk of aortic and mitral regurgitation.Data from the U.S. Food and Drug Administration's adverse reporting system database

2019 EvidenceUpdates

9. Fluoroquinolones: use should be restricted due to severe adverse effects

Fluoroquinolones: use should be restricted due to severe adverse effects Prescrire IN ENGLISH - Spotlight '' Fluoroquinolones: use should be restricted due to severe adverse effects'', 1 September 2019 {1} {1} {1} | | > > > Fluoroquinolones: use should be restricted due to severe adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Fluoroquinolones: use should be restricted due to severe adverse effects Given the many and sometimes severe adverse effects of fluoroquinolone antibiotics, they should only be used for limited purposes. Fluoroquinolones are a group of antibiotics that are effective on many bacteria. But their adverse effects are many and sometimes severe, which has led to the gradual limitation of their use. The European Pharmacovigilance Committee (PRAC) reassessed all adverse reactions to fluoroquinolones in 2018

2019 Prescrire

10. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects

Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports (...) of disabling and potentially long-lasting or irreversible side effects Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation. Published 21 March 2019 From: Therapeutic area: , , , , , , , , , , , , , Contents Advice for healthcare professionals

2019 MHRA Drug Safety Update

11. Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients Full Text available with Trip Pro

Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients - GOV.UK GOV.UK uses cookies to make the site simpler. Search Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients In patients (...) at risk for aortic aneurysm and dissection, fluoroquinolones should only be used after careful assessment of the benefits and risks and after consideration of other therapeutic options. Published 14 November 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: systemic (by mouth or injection) and inhaled fluoroquinolones may be associated with a small increased risk of aortic aneurysm and dissection, particularly in older patients fluoroquinolones should only be used after

2018 MHRA Drug Safety Update

12. Resolution of fluoroquinolone-resistant Escherichia coli keratitis with a PROSE device for enhanced targeted antibiotic delivery Full Text available with Trip Pro

Resolution of fluoroquinolone-resistant Escherichia coli keratitis with a PROSE device for enhanced targeted antibiotic delivery To report the resolution of a fluoroquinolone-resistant Escherichia coli keratitis with use of a prosthetic replacement of the ocular surface ecosystem (PROSE) device for enhanced targeted delivery of moxifloxiacin.A 62-year-old female presented with a 3-day history of pain, photophobia, and declining vision in left eye. The patient had a 2-year history of binocular (...) . Four days later, the corneal surface was epithelialized with only small subepithelial infiltrate remaining. The corneal culture grew an E. coli isolate carrying multiple mutations in the topoisomerase genes. These mutations were correlated with varying levels of resistance to ciprofloxacin (256 μg/mL), levofloxacin (8 μg/mL), and moxifloxacin (16 μg/mL).Although the infecting E. coli strain exhibited resistance to fluoroquinolones, the infection resolved when moxifloxacin was combined with PROSE

2018 American journal of ophthalmology case reports

13. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis Full Text available with Trip Pro

The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis Quinolones were contraindicated during pregnancy because of concerns regarding fetal malformations and carcinogenesis in animals. The literature is conflicting regarding their safety in humans.To conduct a meta-analysis evaluating the risk for fetal malformations and pregnancy complications following exposure to quinolones during pregnancy.We searched Embase, PubMed, Medline, the Cochrane database, clinicaltrials.gov (...) , and Dart Databases. We added articles found through the references of included articles.Relevant English citations using the terms quinolone/s, fluoroquinolone/s, and pregnancy in humans. Exclusion criteria were case reports, reviews, and articles without data regarding the study outcomes.Two authors performed the database search, assessment of eligibility, and abstraction of data from included studies. Disagreement was settled by consensus among all authors. The pooled odds ratios (with 95% CIs) were

2018 EvidenceUpdates

14. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study (Abstract)

Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study To quantify the risk of secondary pseudotumor cerebri syndrome (PTCS) with fluoroquinolones.A case-control study of people 15-60 years of age from the LifeLink Database (QuintilesIMS, Parsippany, NJ) was conducted. Cases had the first ICD-9-CM code for benign intracranial hypertension (BIH) as well as having received a procedure code for an MRI or CT scan and a lumbar puncture within 15 days (...) or 30 days of the BIH code. For each case, 10 controls were selected using density-based sampling. Current users of fluoroquinolones received a prescription within 15 days or 30 days of the date of the diagnosis. For the sensitivity analysis, risk periods for 30 and 60 days were also examined. Adjusted rate ratios (RRs) were computed from a conditional logistic regression model.From a cohort of 6,110,723 people, there were 339 cases of PTCS and 3,390 corresponding controls. In the primary analysis

2017 EvidenceUpdates

15. Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice

Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice | CADTH.ca CADTH Document Viewer Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Table of Contents Search this document Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice May 2017 1. Introduction CADTH undertook a study into antibiotic prescribing and use in Canadian primary care practice, with a particular emphasis (...) on fluoroquinolone use. The study investigated current practices and implementation issues for antibiotic therapies from the perspective of family physicians (FPs), nurse practitioners (NPs), and pharmacists. The research findings are based on the results of qualitative research in the form of surveys of primary care practitioners, as well as on a targeted review of the literature on fluoroquinolones use in Canada. CADTH sought to understand and explain experiences and decision-making processes around outpatient

2017 CADTH - Plasma Products

16. Do fluoroquinolones increase the incidence of adult tendinopathy?

Do fluoroquinolones increase the incidence of adult tendinopathy? BestBets: Do fluoroquinolones increase the incidence of adult tendinopathy? Do fluoroquinolones increase the incidence of adult tendinopathy? Report By: Janos P Baombe - Consultant in Emergency Medicine Search checked by Rebecca Ford - Royal Oldham Hospital, Oldham, Lancashire, UK Institution: Manchester Royal Infirmary, Manchester, UK Date Submitted: 10th February 2017 Last Modified: 10th February 2017 Status: Green (complete (...) ) Three Part Question In [adult patients receiving fluoroquinolone antibiotics] is there [an increased risk] of [developing tendinopathy]? Clinical Scenario You are reviewing urine culture and sensitivity results in your ED. You come across a result growing a germ that is sensitive to ciprofloxacin only. You contact your patient to come and collect a prescription later in the day. Your colleague who has been listening to your phone conversation warns you of the increased risk of tendinopathy

2017 BestBETS

17. Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice

Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice | CADTH.ca Find the information you need Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Last updated: May 1, 2017 Project Number: HT0018-000 - CP0020-000 Product Line: Technology Review Result type: Report The study investigated current practices and implementation (...) issues for antibiotic therapies, particularly fluoroquinolones, for specific indications. The study was conducted from the perspective of family physicians, nurse practitioners, and pharmacists. Indications included: uncomplicated cystitis, uncomplicated pyelonephritis, acute bacterial exacerbation of chronic bronchitis in chronic obstructive pulmonary disease (COPD), and acute bacterial sinusitis. The research findings are based on the results of qualitative research in the form of surveys

2017 CADTH - Technology Review

18. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. Full Text available with Trip Pro

Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. To evaluate if oral fluoroquinolone use is associated with an increased risk of serious arrhythmia.Bi-national cohort study, linking register data on filled prescriptions, cases of serious arrhythmia, and patient characteristics.Denmark, 1997-2011; Sweden, 2006-13.The study cohort was derived from a source population of all Danish and Swedish adults, aged 40 to 79 years. 909,656 courses of fluoroquinolone use (...) (ciprofloxacin 82.6%, norfloxacin 12.1%, ofloxacin 3.2%, moxifloxacin 1.2%, and other fluoroquinolones 0.9%) and 909,656 courses of penicillin V use, matched 1:1 on propensity score, were included.The main outcome was risk of serious arrhythmia (fatal and non-fatal), comparing courses of fluoroquinolone use with courses of penicillin V use (an antibiotic with no pro-arrhythmic effect). The risk period of interest was current use, defined as days 0-7 of treatment. Subgroup analyses were conducted according

2016 BMJ

19. Tavanic (levofloxacin), fluoroquinolone - the treatment of complicated skin and soft tissue infections

Tavanic (levofloxacin), fluoroquinolone - the treatment of complicated skin and soft tissue infections TAVANIC SUMMARY CT12590

2015 Haute Autorite de sante

20. Randomised controlled trial: Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment

Randomised controlled trial: Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment Article Text Therapeutics/Prevention Randomised

2015 Evidence-Based Medicine